Adaptive Biotechnologies Corp: president and COO Julie Rubinstein sold 35,643 shares

What happened

• Julie Rubinstein, president and COO, exercised options to acquire 11,881 shares on each of Oct 19, Oct 20 and Oct 21, 2026 at $12.14 per share (cost $144,235 each day) and sold a total of 35,643 shares in open-market transactions for total proceeds of $879,089. The filing also reports related derivative entries showing 11,881 shares marked as disposed at $0.00 on each of those dates.

Key details

• Transaction dates and prices:
  • Oct 19, 2026: exercised 11,881 shares at $12.14 (acquired $144,235); sold 11,881 shares at weighted average $24.05 (proceeds $285,738). (Footnote F2: sale prices ranged $23.88–$24.85.)
  • Oct 20, 2026: exercised 11,881 shares at $12.14 (acquired $144,235); sold 11,781 shares at weighted average $24.53 (proceeds $288,988) and 100 shares at $24.85 (proceeds $2,485). (Footnote F3: sale prices ranged $23.84–$24.83.)
  • Oct 21, 2026: exercised 11,881 shares at $12.14 (acquired $144,235); sold 5,999 shares at weighted average $25.25 (proceeds $151,475) and 5,882 shares at weighted average $25.57 (proceeds $150,403). (Footnotes F4–F5: sale prices ranged $24.44–$25.73 across those trades.)
• Shares owned after the transactions: not reported in the provided filing excerpt.
• Footnotes:
  • F1: transactions were effected pursuant to a Rule 10b5-1 trading plan adopted Nov 18, 2025.
  • F2–F5: reported sale prices are weighted averages; ranges for individual trades are provided in footnotes.
  • F6: the option exercised is fully vested and exercisable.
• Form 4 filed on Oct 21, 2026 (the filing does not indicate a late filing).

Why it may matter

• The filing shows options were exercised and the acquired shares were sold on the same dates (cashless exercise).
• The filing does not show why the insider traded or why the company acted.